Innoviva

At the H.C. Wainwright conference, Innoviva explained that its business model has evolved from a licensing company into a three‑pillar healthcare platform, with Innoviva Specialty Therapeutics (IST) emerging as the main growth driver. Non‑licensing revenues now exceed traditional quarterly licensing payments, driven by products such as XACDURO, the planned launch of NUZOLVENCE and the addition of ZEVTERA. The company reports strong liquidity and investment reserves of over $1.25 billion and emphasizes that the licensing portfolio with ANORO and BREO continues to provide stable cash flow, while strategic early‑stage investments offer optional upside. » Mais em de.investing.com

Innoviva presented at the Cantor conference a growth strategy based on steady license royalties from its COPD business, a fast-growing specialty therapeutics segment (including XACDURO, GIAPREZA) and the new Nortiva/LYNX oral drug-delivery platform. IST generated over 200 million USD in revenue in the past twelve months and, according to management, is growing 40–50% annually, while Innoviva expects more than 1 billion USD in COPD license fees over the next five years. The company plans continued reinvestment, selective acquisitions and a share buyback program of up to 125 million USD, but sees the long-term need to scale new businesses like Nortiva before COPD revenues wane. International expansion and partner programs in China and emerging markets are intended to advance commercialization of XACDURO and other products. » Mais em de.investing.com

Innoviva Specialty Therapeutics has confirmed three products — XACDURO, ZEVTERA and NUZOLVENCE — as finalists for the Prix Galien USA Award 2026 in the category “best pharmaceutical product.” XACDURO is approved for hospital- and ventilator-associated bacterial pneumonia caused by Acinetobacter, ZEVTERA is a cephalosporin approved in 2024 for Staphylococcus aureus, and NUZOLVENCE is a 2025-approved oral single-dose therapy for resistant gonorrhea. This is the third consecutive recognition of an Innoviva product by the Galien Foundation; the winners will be announced on October 29, 2026. » Mais em de.investing.com